Ledger entry · candidate
Semaglutide → Inappropriate schedule of product administration — Audit-grade candidate (scan)
Drug: semaglutide · AE: Inappropriate schedule of product administration
Discovered via single-drug scan of semaglutide. PRR = 3.34 (95% CI 3.11–3.59), n = 729 cases. Pre-reg locked at submission time.
Disproportionality
- PRR: 3.343443922349501
(95% CI 3.11–3.59)
- Yates χ2: 1199.9791881107706
- Cases (case-drug + AE): n = 729
- Verdict:
PASSES_ALL_GATES — PRR=3.34 (95% CI 3.11–3.59), n=729 cases; flagged for clinical expert review, NOT for external escalation without manual verification
Top reactions in cohort
| MedDRA PT | n |
|---|
| No reactions surfaced in cohort. |
Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.